Agoracom Blog Home

Posts Tagged ‘small cap stocks’

« Older Entries
Newer Entries »

MedX Health Corp. $MDX.ca Announces Third Quarter 2020 Financial Results and Grant of Stock Options $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 8:20 AM on Monday, November 30th, 2020
Home - MedX Health
  • Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019.
  • Revenue from SIAscopy ® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020.
  • Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period.

MedX Health Corp. (“MedX” or “Company”) (TSX-V: MDX) announced its results for the three and nine-months ended September 30, 2020, which are also available on SEDAR ( www.sedar.com ).

The Company reported revenue of $172,889 for the three months ended September 30, 2020, compared with revenue of $234,977 for the three months ended September 30, 2019. Revenue from SIAscopy ® of $74,286 for the third quarter was 29% higher than the prior year three-month period and more than twice that of the three months ending June 30, 2020. Revenue from the Company’s therapeutic laser line of $98,603 was a decrease from $177,436 in the prior year period, but $60,180 higher than in the prior three month period. The Company reported a loss for the three months ended September 30, 2020 of $1,083,772 or $0.01 per share compared with a loss of $577,648, or $0.00 per share for the three months ended September 30, 2019.

The Company reported revenue of $337,885 for the nine months ended September 30, 2020, compared with revenue of $678,886 for the nine months ended September 30, 2019. Revenue from SIAscopy ® of $127,093 was 21% higher than in the first nine months of 2019. Revenue from the Company’s therapeutic laser line of $210,792 for the nine-month period was 63% lower than the $574,069 in the prior year period. The Company reported a loss for the nine months ended September 30, 2020 of $2,532,171 or $0.02 per share, compared with a loss of $2,086,892, or $0.01 per share for the nine months ended September 30, 2019.

“We are pleased that we had strong revenue growth in Q3 compared to Q2, as we more than doubled revenue in each of our product lines,” noted Rob von der Porten, Executive Chairman, and acting CEO. “We made our first shipment of SIAscopy ® units to our Brazilian distribution partner, where they will be deployed on our DermSecure ® platform over the coming months. The sales and marketing team are building a pipeline of international distribution partners for our SIAscopy ® on DermSecure ® telemedicine platform and are experiencing strong interest in the Company’s unique teledermatology platform. While COVID-19 will continue to have an impact on all businesses, it is increasing the interest in telemedicine in general, albeit it is impacting the rate of implementation. While our revenue increased over the second quarter, the loss for the quarter was higher as we built out our sales team, increased marketing efforts, and spent on continued enhancements to our DermSecure ® platform, and as well, we incurred non-cash share-based compensation expense. We remain convinced that we will have long-term, sustainable growth with the MedX DermSecure ® platform and that it is the ‘Gold Standard’ in the teledermatological market space.”

The Company also announces that 800,000 stock options have been granted to Directors. Such options have an exercise price of $0.17 per share, will expire on November 25, 2025, and vest immediately.

MedX also announces it has retained Venture North Capital Inc. (“Venture North”) for strategic marketing, investor relations and capital markets communications services. Venture North will arrange and attend meetings with professional investors, maintain ongoing contact and broaden relationships with the professional investment community on MedX’s behalf.

Under the terms of the agreement, MedX will pay Venture North a monthly fee of $6,000 for ongoing strategic services for an initial six (6) months, after which the relationship will continue on a monthly basis. The agreement may be terminated by MedX or Venture North on 60 days written notice. Venture North will also be granted stock options (the “Options”), totaling up to 900,000 common shares of the Company, which will vest and become exercisable quarterly with 225,000 of the options vesting on each of the dates that are three, six, nine and twelve months from the beginning of the Engagement Period. The Options will be exercisable at a price of $0.17 per share for a period of two years. The appointment and option grant are subject to TSX Venture Exchange approval.

Summary of Recent Announcements:

The following is a summary of recent announcements made by the Company, for which further details can be found under the Company’s profile at www.sedar.com .

MedX Announces Sales Agency Agreement with Ziemer Professional Corp.

On October 28, 2020, the Company announced it had completed a sales agency agreement with the Ziemer Professional Corporation. Ziemer will target its sales efforts within the medical, athletic, and pain management clinic markets. Six new clinics will begin installing the SIAscopy ® on Dermsecure ® telemedicine platform across Ontario and Saskatchewan.

MedX Adds Two New Members to Board of Directors

On October 15, 2020, the Company appointed Anthony Milonas and Wayne Cockburn as Directors of the Company. Mr. Milonas and Mr. Cockburn bring extensive senior management experience working with medical device and health care growth-stage companies, both nationally and internationally. Mr. Milonas is President and CEO of Canadian Orthodontic Partners, a company overseeing a national network of orthodontic practices. Mr. Cockburn is President of The Clinic Network Canada, one of Canada’s largest providers of out-of-hospital pain management services.

MedX Expands Senior Leadership Team

On September 21, 2020, the Company announced the appointment of veteran healthcare industry executive Naman Demaghlatrous as Managing Director, Europe, Middle East & Africa (“EMEA”), and Chantal Ward, RN, as Director, Dermatological Services. Mr. Demaghlatrous brings more than 20 years of experience in the healthcare industry, including roles with companies such as Medtronic, Pediapharm, Johnson & Johnson and Atfal Pharma. Chantal Ward, RN, a Diploma Nurse Graduate with an operating room background, has 20+ years’ experience as a clinical trainer of advanced medical aesthetic equipment and technology.

MedX Announces Management Changes and Increased Focus on SIAscopy® on DermSecure®

On September 9, 2020, the Company announced management changes to enhance its focus on its dermatological services and products including DermSecure ® and SIAscopy ® . Mike Druhan, who has championed SIAscopy ® within the Company for a number of years, has been appointed President, Dermatological Services and Products. Louie Canitano, who has many years of experience in therapeutic laser and light products has been appointed Managing Director, Light Therapy Products.

MedX Announces Closing of Non-Brokered Private Placement

On August 4, 2020, the Company announced that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,666 units at $0.12 per unit (“Unit”), to raise up to $2,000,000, the closing of a first tranche of that placement has taken place on July 31, 2020, for a total of 2,600,000 units, raising a total of $312,000. Each Unit is comprised of One (1) fully paid common share and One (1) Share Purchase Warrant, exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period of two years from the date of issue. The securities issued will be restricted from trading for four months from the date of issue. In connection with this tranche of the private placement, cash commissions of $24,000 were paid.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ® on DermSecure ® telemedicine platform, utilizing its SIAscopy ® technology. SIAscopy ® is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com .

This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005362/en/

MedX Health Corp
Rob von der Porten
[email protected]

Investor Relations
Bill Mitoulas
[email protected]
Tel: +1.416.479.9547

Tags: , , , , , , , ,
Posted in MedX Health Corporation | Comments Off on MedX Health Corp. $MDX.ca Announces Third Quarter 2020 Financial Results and Grant of Stock Options $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Files Patent Applications With the U.S. Patent and Trademark Office and the Canadian Intellectual Property Office for Its #Biocloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 8:15 AM on Monday, November 30th, 2020
kontrol-logo
  • Announced that as a follow up to its press release dated September 23rd, 2020, the Company has filed four patent applications for its BioCloudTM Technology.
  • Four patent applications have been filed, three with the U.S. Patent and Trademark Office and one with the Canadian Intellectual Property Office : SYSTEM AND METHOD FOR DETECTING AIRBORNE PATHOGENS

TORONTO, ON / November 30, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company”) a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology is pleased to announce that as a follow up to its press release dated September 23rd, 2020, the Company has filed four patent applications for its BioCloudTM Technology.

Four patent applications have been filed, three with the U.S. Patent and Trademark Office and one with the Canadian Intellectual Property Office : SYSTEM AND METHOD FOR DETECTING AIRBORNE PATHOGENS.

“These patent applications address key attributes of our technology, which utilizes a combination of continuous air quality monitoring and a proprietary detection chamber to target and identify airborne pathogens to help create safer spaces,” says Paul Ghezzi, CEO Kontrol. “We are very proud of our team and the milestone this represents. Innovation is at the core of our operations and we continue to execute on our plans.”

About Kontrol BioCloud

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware and service solutions to its customers to improve energy management, air quality and deliver continuous emission monitoring.

Additional information about Kontrol Energy Corp. and BioCloud can be found on its websites at www.kontrolenergy.com and www.kontrolbiocloud.com, and by reviewing its profile on SEDAR at www.sedar.com


For further information, contact:

Paul Ghezzi, Chief Executive Officer
[email protected] or [email protected]
Kontrol Energy Corp.
180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8
Tel: 905.766.0400, Toll free: 1.844.566.8123

Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.

However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer (BioCloud) are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.

Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.

SOURCE: Kontrol Energy Corp.

Tags: , , , , , , , , , ,
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Files Patent Applications With the U.S. Patent and Trademark Office and the Canadian Intellectual Property Office for Its #Biocloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Empower Clinics $CBDT.ca $EPWCF Signs North American Distribution Agreement with API Pharma USA For FDA EUA #COVID-Rapid Antigen & Antibody Tests. Supported Three Months of Clinical Trials $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:21 AM on Monday, November 30th, 2020
  • Announce the North American Re-Seller & Distribution Agreement with API Pharma (“API”) for its FDA EUA submitted Rapid Antigen Test and Rapid Antibody Test.
  • Empower’s KAI Medical Laboratory provided API significant scientific data through three months of clinical trials.
  • As a result, Empower and API are now able to sell these products with confidence, on an unlimited basis, to its customers and prospective customers nationwide in the United States and in European countries supporting CE mark approval.

VANCOUVER, BC / November 30, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the Southwest United States, a telemedicine platform and medical diagnostics laboratory is pleased to announce the North American Re-Seller & Distribution Agreement with API Pharma (“API”) for its FDA EUA submitted Rapid Antigen Test and Rapid Antibody Test.

Empower’s KAI Medical Laboratory (“KAI”) provided API significant scientific data through three months of clinical trials. As a result, Empower and API are now able to sell these products with confidence, on an unlimited basis, to its customers and prospective customers nationwide in the United States and in European countries supporting CE mark approval.

Furthermore, Empower and KAI are providing API with support for its Health Canada submission for its Rapid Antigen Detection Test (“RADT”) (COVID-19 Application For Authorization If Import Or Sale Of Medical Devices). Empower will have Canadian distribution rights upon Health Canada approval.

Steven McAuley, Chairman and CEO of Empower stated “Our society is experiencing unprecedented changes that are affecting how we go back to work, how we travel and how we might gain permission to interact with others. Testing protocols and testing products are becoming a part of our daily lives, and there are key differences between PCR, antigen and antibody tests. They are all important, irrespective of how potential vaccines come to market. Our company is leading and positioned to provide all of these important tests to the markets we serve.”

The global COVID-19 diagnostics market size is valued at USD 19.8 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 3.1% from 2021 to 2027. These tests are critical in the management of the ongoing COVID-19 pandemic for accurate diagnosis as well as for tackling the spread of the infection (https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market)

WHAT IS A RAPID ANTIGEN DETECTION TEST (RADT)?

An RADT is a rapid diagnostic test suitable for point-of-care testing that directly detects the presence or absence of an antigen. This distinguishes it from other medical tests that detect antibodies or nucleic acid, of either laboratory or point of care types.

WHAT IS AN ANTIBODY TEST?

An antibody test, also known as a serology test, looks for specific antibodies in your blood. This test is useful because it shows if someone has had the infection in the past, even if you had only mild symptoms.

One inherent advantage of an antigen test over an antibody test is that it can take time for the immune system to develop antibodies after infection begins, but the foreign antigen is present within a preliminary incubation period of five days or less.

GOVERNMENT OF CANADA – RADT’s WILL HAVE AN IMPORTANT ROLE TO PLAY

The Government of Canada website for the use of RADT stated the following”

“Potential characteristics of these tests (faster turnaround time, lower per-test cost, ability to do the test in a setting by non-professionals on a more frequent basis, amongst others) suggest that they will have an important role to play in the next phase of the response. It is important for the public health, infectious diseases experts and laboratory communities to identify the scenarios where the use of RADTs may further strengthen the public health response by expanding access to testing”

(https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-detection-tests.html)

API PHARMA – NO CHOICE BUT TO RAPID TEST

Rapid testing is critical to any strategy for containing COVID-19. It helps determine where the virus is spreading, who has immunity and how widely the virus has spread.

The COVID-Rapid Antigen Test determines who has the virus at present and is likely to be contagious. With >99% sensitivity for those who are contagious, the rapid results allow healthcare providers to make quick and accurate medical decisions.

The COVID-Rapid Antibody Test, which screens blood for antibodies, can allow hospitals and workplaces to identify people who were infected and may have already developed immunity. Studies have shown that one-third to one-half of those infected with COVID-19 are asymptomatic. As a result, serology tests help determine who can lead the way back to reopen businesses and work on the front lines of health care.

The COVID-Rapid line of tests are accurate and affordable so it can be used for testing large populations. America has no choice but to rapid test for COVID-19 so that governments, schools, and workplaces can test large groups of individuals, not just those who present with symptoms.

API PHARMA RADT DEMONSTRATED HIGHLY EFFECTIVE ON 3 CONTINENTS

API Pharma’s COVID-Rapid Antigen test has been tested and demonstrated to be highly effective on three continents. This is important as it demonstrates all the different strains of the virus will respond equally to the rapid antigen test. Clinical studies were carried out specifically in China, the United States and Poland.

PARTNERSHIP FURTHER SOLIDIFIES KAI MEDICAL FOOTHOLD IN COVID-19 TESTING SPACE

The clinical trials of API products performed a variety of studies including the precision, accuracy, sensitivity, and interfering substances, as well as, the efficacy of operators to perform the test accurately. These studies ensure that API-products meet industry standards for testing and will accurately identify COVID-19 positives as well as COVID-19 negatives.

Because of API’s focus on Rapid, Point-of-Care testing for both antibodies and antigens, in addition to Kai Medical’s extraordinary capacity to handle industry-standard turnaround times for RT-PCR testing, this partnership further solidifies Kai Medical’s foothold in the COVID-19 testing space.

Yoshi Tyler, President of KAI Medical Laboratory stated “We anticipate that, moving forward, there will be a focus on much more rapid and accurate point-of-care testing, in order to return to everyday life. Like the virus, our testing strategies must be adaptable. As we move forward, we continue to prioritize the best and most efficacious testing strategies.”

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including movie and television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

ABOUT API PHARMA

API Pharma (API) is an industry leader in designing and distributing rapid tests for a range of viruses and diseases, including rotovirus, influenza, hepatitis, herpes, HIV, and others.

API’s rapid COVID-19 test is nearly as simple as a home pregnancy test, requiring only a few drops of blood from a finger stick and a drop of reagent. Results are available in under 20 minutes and are simple to interpret: one line means negative, two lines means positive. The test has 97% sensitivity and 97% specificity, and API’s long experience with rapid tests makes it a reliable provider. API currently has approval to provide test kits to medical facilities in the U.S. and expects to have FDA approval for home use soon. The test is already in use in Europe.

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ABOUT Kai Medical Laboratory

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca $EPWCF Signs North American Distribution Agreement with API Pharma USA For FDA EUA #COVID-Rapid Antigen & Antibody Tests. Supported Three Months of Clinical Trials $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

SustainCo $SMS.ca Announces Name Change and New Ticker Symbol – > Universal PropTech $UPI.ca

Posted by AGORACOM-JC at 11:44 AM on Friday, November 27th, 2020
  • Announced today that, further to its press release dated November 10, 2020, it has changed its name from “SustainCo Inc.” to “Universal PropTech Inc.“

Toronto, Ontario–(November 27, 2020) – SustainCo Inc. (TSXV: SMS) (“SustainCo” or the “Company“) announces today that, further to its press release dated November 10, 2020, it has changed its name from “SustainCo Inc.” to “Universal PropTech Inc.“

At the opening of the markets on December 1, 2020, the Company’s common shares will commence trading under the new name Universal PropTech Inc. and the new ticker symbol “UPI”. The Company’s new CUSIP number is 91380M100 and its new ISIN is CA91380M1005.

The Company has launched its new logo, brand and website, www.UniversalPropTech.com.

There is no consolidation of the Company’s share capital in connection with the name change. As a result, shareholders are not required to exchange either existing share certificates for new certificates bearing the Company’s name. The name change does not affect the Company’s share structure or the rights of the Company’s shareholders, and no further action is required by existing shareholders.

“Universal PropTech is delivering de-risked proptech investments by using our 40 years HVAC/Building Controls company to integrate proptech into healthy buildings,”  stated Chris Hazelton, Chief Executive of Officer of Universal PropTech Inc. “We are actively seeking new proptech investments to bring to market in Canada.”

The Company also announces today that, further to its press release dated November 23, 2020, it has issued an aggregate of 60,536 common shares at a deemed exercise price of $0.28 per share in connection with the first payment of $15,000 + HST due to Agoracom Internet Relations Corp. pursuant to the advertising agreement with the Company dated November 17, 2020. The common shares are subject to a 4 month plus one day hold period.

About Universal PropTech Inc.

Universal PropTech Inc. (TSXV: UPI), conducts its operations through its wholly-owned subsidiary, VCI Controls Inc. (“VCI“), a leading supplier and integrator of proptech healthy building solutions and services. The Company is an industry leader in the development of intelligent building technology, including the integration of all building systems utilizing the latest in communications technologies and standards. VCI’s business focuses on digital controls and mechanical services, performance monitoring, and energy efficiency solutions.

With headquarters in Toronto, Universal PropTech has offices across Canada including, Halifax, Montreal, and Ottawa. For more information, visit www.universalproptech.com.

Forward-Looking Statements

Certain information provided in this press release constitutes forward-looking statements and information within the meaning of applicable securities laws. Forward-looking information typically contains statements with words such as “anticipate”, “believe”, “forecast”, expect”, “plan”, “intend”, “estimate”, “propose”, “project”, or similar words suggesting future outcomes. The Company cautions readers and prospective investors in the Company’s securities not to place undue reliance on forward-looking information as, by its nature, it is based on current expectations regarding future events that involve a number of assumptions, inherent risks and uncertainties, which could cause actual results to differ materially from those anticipated by the Company.

The forward-looking information included herein is expressly qualified in its entirety by this cautionary statement. The forward-looking information included herein is made as of the date hereof and the Company assumes no obligation to update or revise any forward-looking information to reflect new events or circumstances, except as required by law.

Neither the Exchange, nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

CONTACT INFORMATION

Universal PropTech Inc.
Chris Hazelton
Chief Executive Officer
(647) 300-2957

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69098

Tags: , , , , , ,
Posted in Universal PropTech Inc. | Comments Off on SustainCo $SMS.ca Announces Name Change and New Ticker Symbol – > Universal PropTech $UPI.ca

The Top 5 Industries That Will Benefit the Most From Augmented Reality #AR – SPONSOR: Imagine AR $IP.ca $IPNFF $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 11:19 AM on Friday, November 27th, 2020

SPONSOR: Imagine AR Inc. (IP:CSE) (IPNFF:OTCQB) is an Augmented Reality platform that allows businesses to easily launch AR campaigns. Clients Include: NBA Sacramento Kings, Mall of America, AT&T Shape and The Basketball Hall of Fame. ImagineAR and NFL Alumni Academy recently signed a 5 year partnership agreement. The company was selected by Canadian pharmacy chain Shoppers Drug Mart to deliver Immersive AR Conference Experience and if that’s not enough, Imagine AR just signed its second La Liga team to provide AR experiences for fans.  Learn More.

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

The Top 5 Industries That Will Benefit the Most From Augmented Reality

By Roger Bishop

Augmented reality and virtual reality get most of their fame from the videogame industry, but the more practical uses are becoming more and more utilized across almost every major industry in the United States. Virtual reality is a complete sensical change from an individual’s given surrounding, and generally involves putting on some kind of encompassing headgear that shuts out what is actually around the users. Augmented reality, on the other hand, utilizes technology created to interact with reality, “augmenting” what is actually already there. One of the simplest examples would be a photo filter on your phone that adds sunglasses to whomever you’re taking a picture of. This article will take a look at 5 industries that can (or are already) benefit from evolutions in Augmented Reality (AR).

Construction

Augmented reality in construction can serve a number of purposes, with two of the most important being in safety and saving money. The U.S. construction business generates more than $1.2 trillion every year, and employs more than 7 million Americans. With that many players in the game, even pennies saved here and there can add up quickly. Recent trends, mainly caused by regulation and availability from the public sector, have shown lacks of productivity in the construction industry caused by poor design, poor management, and lacks in development.

AR models can help identify design issues before building starts, saving time and money, and can also help during construction, showing precise directions regarding certain installations and trades. AR is also being heavily utilized in training, and the construction sector is following suit.

Rehabilitation

The uses for AR in healthcare are aplenty, and growing by the day; however, most uses are still in a “clinical trials” phase to determine what is working and what is not. When it comes to rehab, though, AR is already a proven means of increasing therapy outputs. For PTSD, in particular, augmented reality programs can help patients take very small “doses” of whatever causes their trauma in an attempt to slowly ween them off the fear. For soldiers, this can mean subtly adapting to loud noises in a controlled environment until those noises and interruptions no longer act as triggers for past traumatic experiences.

Nursing

For nursing, training is a part of the weekly grind. From cultural diversity training to new procedures, nurses are permanently learning, and AR is giving them a chance to do so in a much more effective manner. Smart glasses are a new technology that allow nurses to work on a patient while having information about the procedure appear, literally, right in front of their eyes on a glass screen that is something out of a James Bond film. This AR training also allows for nurses to get more experience without actually working on a sick individual.

Education

As a whole, the education sector serves to benefit greatly from AR as well. For trade schools, the possibilities are almost endless, but even general, every day education is enacting some forms of augmented reality into their curriculums. There are many AR apps being tailored for education, and as long as schools can provide equal means of utilizing these technologies among all students, the interactive aspects are expected to help students stay focused, as well.

Video Games

Of course, video games are still the industry that most of us first saw AR in action, with the Pokemon Go’s of the world, and the industry certainly isn’t shying away from AR now that it’s becoming popular in other sectors of business. Global augmented reality is the “new future” and allows gamers to, literally, see things that only exist digitally, all across the actual world we live in and breath on every day.

Source: https://www.universenewsnetwork.com/2020/11/27/the-top-5-industries-that-will-benefit-the-most-from-augmented-reality/

Tags: , , , , , , , , , , , ,
Posted in All Recent Posts, Imagine AR | Comments Off on The Top 5 Industries That Will Benefit the Most From Augmented Reality #AR – SPONSOR: Imagine AR $IP.ca $IPNFF $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

#AI to Boost Military Info-Tech Market – SPONSOR: KWESST Micro Systems $KWE.ca $WRTC $BYRN.ca $PAT.ca $POWW

Posted by AGORACOM-JC at 9:54 AM on Friday, November 27th, 2020

SPONSOR POST:

WHY KWESST? HERE’S SOME GREAT REASONS

1.   KWESST is a leader in defensive technologies that increase the capabilities of soldiers, including
those of NATO and its allies. 

2.  These technologies make a critical difference to soldier safety and effectiveness. 

3.  The Leadership team experience spans decades and hundreds of millions of dollars in military and homeland security contracts.

4.  KWESST develops next-generation systems for forces around the world, with a particular focus on special forces among NATO countries and their allies.

Image-1

5.  KWESST partners with globally recognized equipment manufacturers to integrate its systems into
their solutions to create high value-add products for global customers.

Image-2

AI to Boost Military Info-Tech Market

  • Pentagon spending on artificial intelligence is expected to grow faster than the overall defense information-technology market, according to one analyst.
  • Eighteen contracts with a total value of $489 million were awarded by the Defense Department in 2019 for AI products and services, noted Brad Curran, industry principal for aerospace, defense and security at Frost & Sullivan.

By Jon Harper

While military spending on IT is projected to increase about 2 percent in 2021, artificial intelligence is projected to do better within that portfolio over the short-, medium- and long-term, he said during a recent webinar.

The Pentagon established the Joint Artificial Intelligence Center in 2018, and each of the services and many other organizations within the Defense Department are also doing their own work with the technology, he noted.

“The contracts to assist analysts and to assist human understanding, to be able to take large amounts of data and do predictive analytics is very important to DoD for logistics, for maintenance, for intelligence, for communications, to be able to make the best possible use of the crowded frequency spectrum,” he said. “Many different areas are using artificial intelligence more and more within DoD.”

Contract trends include computer vision engineering to improve network performance, and containerized and deployable machine learning systems, according to his presentation slides.

The market represents an opening for commercial firms, he noted. However, they might not always be able to sell commercial-off-the-shelf systems.

“Firms that provide artificial intelligence software and services … have to be flexible enough to modify their products to be able to work within and for a larger systems integrator or in contracting directly with DoD, to make sure that they are able to bring operational advantages,” he said. “They may have to modify it a bit and make sure that they’re meeting DoD operational needs.”

In addition to bidding on contracts directly, commercial companies can get their foot in the door of the military acquisition enterprise by working with large systems integrators, he noted.

“They’re always looking for subcontractors,” Curran said. “It’s a great way to break into the DoD market by partnering with established DoD network providers.”

Source: https://www.nationaldefensemagazine.org/articles/2020/11/12/ai-to-boost-military-info-tech-market

Tags: , , , , , , , ,
Posted in All Recent Posts, KWESST Micro Systems Inc. | Comments Off on #AI to Boost Military Info-Tech Market – SPONSOR: KWESST Micro Systems $KWE.ca $WRTC $BYRN.ca $PAT.ca $POWW

Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF to Report Third Quarter 2020 Results on November 30, 2020 $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 4:45 PM on Thursday, November 26th, 2020
kontrol-logo
  • Will report its financial results for the nine months ended September 30, 2020 on November 30th, 2020.
  • A call to discuss the financial results has been scheduled for Monday, November 30th, 2020 at 4:30pm (EST).
  • https://www.webcaster4.com/Webcast/Page/2402/39051

TORONTO, ON / November 26, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company”) a leader smart buildings and smart cities through IoT, Cloud and SaaS technology will report its financial results for the nine months ended September 30, 2020 on November 30th, 2020.

A call to discuss the financial results has been scheduled for Monday, November 30th, 2020 at 4:30pm (EST). A complete set of Financial Statements and Management’s Discussion & Analysis will be filed on SEDAR (www.sedar.com) on Monday, November 30th, 2020.

Event Details:

Title:Kontrol Energy Third Quarter 2020 Financial Results
Event Date:Monday, November 30th, 2020 – 4:30PM Eastern Time
Event Duration:45 Minutes
Event Link:Webcast URL : https://www.webcaster4.com/Webcast/Page/2402/39051
Participant Number:Toll Free: 877-407-0782
International: 201-689-8567


Please connect at least 5 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.

About Kontrol Energy

Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in smart buildings and smart cities through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com

Tags: , , , , , , , ,
Posted in Kontrol Energy Corp. | Comments Off on Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF to Report Third Quarter 2020 Results on November 30, 2020 $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

AGORACOM Small Cap 60: Sheldon Inwentash $IDK.ca $IDKFF One of The Greatest Investors In Canadian History Discusses Investment Philosophy $PKK.ca $PKKFF $MTRX.ca $RACMF

Posted by AGORACOM-JC at 3:51 PM on Thursday, November 26th, 2020
IDK-square-for-blog

Sheldon Inwentash shares his current investment philosophy, focusing on global debt and currency devaluation along with his appetite for digital and other disruptive technologies.  

Mr. Inwentash has more than 30 years of investing experience and has been instrumental in raising $15 billion for his portfolio companies over the last 15 years. He co-founded Visible Genetics, the first commercial pharmacogenomics company, in 1994 and exited in 2001 to Bayer. Through two decades leading Pinetree Capital, Mr. Inwentash created significant shareholder value through early investments in Queenston Mining (acquired by Osisko Mining Corp. for $550-million), Aurelian Resources (acquired by Kinross for $1.2-billion) and Gold Eagle Mines (acquired by Goldcorp for $1.5-billion) to name a few.

Tags: , , , , , , , , , , , ,
Posted in AGORACOM Small Cap 60, All Recent Posts, ThreeD, ThreeD Capital | Comments Off on AGORACOM Small Cap 60: Sheldon Inwentash $IDK.ca $IDKFF One of The Greatest Investors In Canadian History Discusses Investment Philosophy $PKK.ca $PKKFF $MTRX.ca $RACMF

Empower $CBDT.ca $EPWCF Reports Q3 2020 Results With 67% Revenue Increase for The Nine Months Ended September 30, 2020 $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:33 AM on Wednesday, November 25th, 2020
  • 5,044 patient visits generating total revenue of $629,854, compared to 5,807 patient visits generating $663,003 for Q3 2019.
  • 17,457 patient visits generating total revenue of $2,306,111, compared to 11,304 patient visits generating $1,409,143 for nine months ended September 30, 2019.

VANCOUVER, BC / ACCESSWIRE / November 25, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (OTC PINK:EPWCF) (Frankfurt:8EC) (“Empower” or the “Company”) has filed today its unaudited condensed interim financial statements and related management’s discussion and analysis, both of which are available at www.SEDAR.com. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

“Our Q3 2020 performance overall exceeded our expectations given the challenging operating environment in our key markets, yet the team managed to serve large quantities of patients while maintaining strict COVID-19 protocols for health and safety.” Said Steven McAuley, Chairman and CEO. “We also continue to implement numerous business development opportunities setting the stage for an exciting Q4 and 2021.”

Q3 2020 Highlights

  • 5,044 patient visits generating total revenue of $629,854, compared to 5,807 patient visits generating $663,003 for Q3 2019.
  • Net loss of $460,035 or $0.00 per share, compared to a loss of $504,532 or $0.00 per share for Q3 2019, driven by increases in direct clinic costs as a percentage of revenue. This issue was addressed subsequent to the quarter by changing the compensation structure of the clinic’s physicians along with the implementation of further cost cutting measures in Arizona clinics.
  • Cash used in operating activities was $534,141, compared to $487,720 for Q3 2019.
  • Cash at September 30, 2020 of $112,539, compared to cash of $179,153 at December 31, 2019.

YTD 2020 Highlights

  • 17,457 patient visits generating total revenue of $2,306,111, compared to 11,304 patient visits generating $1,409,143 for nine months ended September 30, 2019.
  • Net loss of $1,380,316 or $0.01 per share, compared to a loss of $2,359,579 or $0.02 per share for nine months ended September 30, 2019, driven by year to date increased profitability related to the Sun Valley Health acquisition and robust reductions in salaries and benefits, legal and professional fees and non-cash share-based payments expense.
  • Cash used in operating activities was $531,494, compared to cash used in operating activities of $1,819,670 for nine months end September 30, 2019.

Financial Performance for the nine months ended September 30, 2020

Increase in clinic revenues – The increase is attributed to the acquisition of Sun Valley in 2019 and the addition of 5 clinics for the full reporting period.

Increase in direct clinic expenses – This increase above prior year is attributable to the increase in number of patient visits and the related physician costs.

Decrease in loss from operations – This decrease in net loss from operations primarily attributable to an increase in clinic profitability with the acquisition of Sun Valley and a decrease in salaries and benefits, legal and professional fees and non-cash share-based payments expense.

Loss from operations for the quarter – The loss for the quarter is comparable to the loss for the same quarter in 2019. While able to reduce legal and professional fees for the quarter, there was an increase in direct clinic costs. This issue was addressed subsequent to the quarter by changing the compensation structure of the clinic’s physicians.

Please refer to the Company’s unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 and 2019, and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the fact that Kai Medical Laboratory will complete the development of ABC RT-PCR test; the development of new accounts using the new test; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: , , , , , , ,
Posted in Empower Clinics Inc., Featured | Comments Off on Empower $CBDT.ca $EPWCF Reports Q3 2020 Results With 67% Revenue Increase for The Nine Months Ended September 30, 2020 $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

ImagineAR $IP.ca $IPNFF Signs Two Year Partnership Agreement with Real Sociedad of La Liga To Provide Interactive Augmented Reality Experiences for Fans $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:28 AM on Wednesday, November 25th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Real Sociedad is Second La Liga Team to Leverage Augmented Reality for Fan Activation & Engagement with ImagineAR

  • Announced the signing of a two year revenue partnership agreement with Real Sociedad, two time La Liga Champion and currently first place in La Liga, to provide its Augmented Reality SDK Platform for fan activation and engagement
  • This agreement makes Real Sociedad the second La Liga team to incorporate ImagineAR SDK Augmented Reality for global fan activation and engagement

VANCOUVER, BC and ERIE, Pa. , Nov. 25, 2020 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) (“ImagineAR” or “Company”) an Augmented Reality Company that enables sports teams, businesses and enterprises to instantly create their own AR mobile campaigns, is pleased to announce the signing of a two year revenue partnership agreement with Real Sociedad, two time La Liga Champion and currently first place in La Liga, to provide its Augmented Reality SDK Platform for fan activation and engagement. This agreement makes Real Sociedad the second La Liga team to incorporate ImagineAR SDK Augmented Reality for global fan activation and engagement.

Juan Iraola , Chief Innovation Officer at Real Sociedad and Sports Innovation Alliance, stated “We focus on integrating best-in-class technology and ImagineAR provides the most advanced Augmented Reality SDK fan engagement platform for mobile apps today.  We are excited to launch immersive AR campaigns for Real Sociedad fans around the world starting in 2021.”

Alen Paul Silverrstieen, CEO of ImagineAR, stated ” Juan Iraola is recognized as a global sports technology thought leader and we are excited to be working with Real Sociedad for the next two years delivering immersive fan engagement and sponsorship activation. We are very optimistic that this partnership will grow enormously in the next two years.”

This News Release is available on the company’s CEO Verified Discussion Forum , a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About ImagineAR

Imagine AR Inc. (CSE: IP) (OTC: IPNFF) has developed ImagineAR.com; an “AR-as-a-Service” platform for desktops that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds using ImagineAR. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage with videos,
information, advertisements, coupons, 3D holograms and any interactive content, all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The ImagineAR mobile app is available in the IOS and Android mobile app stores. The platform is available as a native mode SDK.

For more information or to explore working with ImagineAR, please email; [email protected] or visit www.imagineAR.com .

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO
(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if ImagineAR Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward- looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: , , , , , , , , , , , , , ,
Posted in Featured, Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF Signs Two Year Partnership Agreement with Real Sociedad of La Liga To Provide Interactive Augmented Reality Experiences for Fans $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

« Older Entries
Newer Entries »